Acrivon Therapeutics (NASDAQ:ACRV) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a research note released on Monday, Benzinga reports. They currently have a $22.00 price objective on the stock.

ACRV has been the subject of a number of other reports. Piper Sandler Companies reiterated a buy rating and issued a $30.00 target price on shares of Acrivon Therapeutics in a research note on Friday, September 6th. LADENBURG THALM/SH SH raised shares of Acrivon Therapeutics from a neutral rating to a buy rating and set a $16.00 price objective for the company in a research note on Monday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Acrivon Therapeutics has a consensus rating of Buy and a consensus target price of $23.86.

Acrivon Therapeutics Price Performance

Shares of ACRV opened at $7.56 on Monday. The business’s 50-day moving average is $8.18 and its 200-day moving average is $7.68. The company has a market capitalization of $233.43 million, a price-to-earnings ratio of -2.65 and a beta of 0.81. Acrivon Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $11.90.

Acrivon Therapeutics (NASDAQ:ACRV) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.08. Equities research analysts expect that Acrivon Therapeutics will post -2.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Acrivon Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Acrivon Therapeutics by 6.6% during the 1st quarter. Vanguard Group Inc. now owns 507,185 shares of the company’s stock valued at $3,626,000 after purchasing an additional 31,208 shares during the last quarter. American International Group Inc. increased its holdings in shares of Acrivon Therapeutics by 39.2% during the 1st quarter. American International Group Inc. now owns 6,016 shares of the company’s stock worth $43,000 after purchasing an additional 1,695 shares during the period. Baker BROS. Advisors LP acquired a new position in shares of Acrivon Therapeutics during the first quarter valued at about $378,000. Bank of New York Mellon Corp lifted its stake in shares of Acrivon Therapeutics by 50.1% in the second quarter. Bank of New York Mellon Corp now owns 36,632 shares of the company’s stock valued at $212,000 after buying an additional 12,219 shares during the period. Finally, Rhumbline Advisers grew its position in Acrivon Therapeutics by 48.9% during the second quarter. Rhumbline Advisers now owns 16,209 shares of the company’s stock worth $94,000 after buying an additional 5,320 shares in the last quarter. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.